Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Gilead

Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?

Gilead Sciences has recently demonstrated strong performance, outperforming the broader healthcare sector, and analysts maintain a cautiously optimistic outlook on its future.

Barchart

Looking At Gilead Sciences's Recent Unusual Options Activity

Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences (NASDAQ:GILD).

Benzinga

A twice-yearly shot could help end AIDS. But will it get to everyone who needs it?

A twice-yearly shot that prevents HIV infections will be available at low cost in 120 poor countries

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Biotech Stocks with Promising Pipelines to Watch

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

StockNews.com

Fewest New HIV Cases Since Late 1980s: UNAIDS Report

Fewer people contracted HIV last year than at any point since the rise of the disease in the late 1980s, the United Nations said Tuesday, warning that this decline was still far too slow.

International Business Times

'Remarkable Global Progress': HIV Cases And Deaths Declining

The number of new HIV infections and deaths has fallen across the world, marking significant progress in the fight against the disease.

International Business Times

Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review

The stock market surged to highs on Donald Trump's election win. A Fed rate cut and a slew of big earnings reports filled out a busy week.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Gilead Sciences Stock: Analyst Estimates & Ratings

Gilead Sciences has underperformed the broader market over the past year, but Wall Street analysts are moderately optimistic about the stock’s prospects.

Barchart

Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise

Gilead stock sprinted to a profit-taking zone Thursday after Gilead Sciences rode its Covid treatment to another beat and raise.

Investors Business Daily

3 Biotechnology Stocks With Promising Pipelines

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming. Therefore, it could be wise to invest in solid biotech stocks Amgen (AMGN), Regeneron Pharmaceuticals (REGN), and Gilead Sciences (GILD) for substantial returns. Read more.

StockNews.com

3 Top Healthcare Stocks to Buy for Growth and Dividends

Investors seeking growth and dividend income in the healthcare sector may want to consider Eli Lilly, Gilead Sciences, and Amgen, which have delivered impressive returns and boast strong pipelines and strategic moves.

Barchart

Gilead Sciences’ Quarterly Earnings Preview: What You Need to Know

Gilead Sciences is scheduled to report its fiscal third-quarter earnings next month, and analysts anticipate a lower-double-digit drop in its EPS.

Barchart

3 Biotech Stocks Set to Revolutionize Medicine

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To capitalize on the industry’s expansion, it could be wise to invest in fundamentally sound biotech stocks, Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which have the potential to revolutionize medicine. Read…

StockNews.com

Gilead’s biannual HIV shot reduced risk of infections by 96 percent, company says

The drugmaker said its injections were 89 percent more effective than its own Truvada

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention

Gilead stock popped Thursday after the biotech giant said its twice-yearly shot prevented 99.9% of HIV infections in a study.

Barchart

Is Gilead Sciences Stock Underperforming the Dow?

Despite Gilead Sciences' underperformance relative to the Dow Jones Industrial Average over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Investors Business Daily

Gilead Stock Dips As 'Non-Core' Products Drive Its Second-Quarter Beat

Gilead stock dipped Friday after beating second-quarter expectations on the back of stronger-than-expected sales of non-core products.

Barchart

Do Wall Street Analysts Like Gilead Sciences Stock?

Gilead Sciences has underperformed the broader market over the past year, yet Wall Street analysts remain moderately bullish about the stock’s prospects.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Experts say a twice-yearly injection that offers 100% protection against HIV is 'stunning'

A study shows that a twice-yearly shot was 100% effective in preventing new HIV infections in women in Africa

International Business Times

UN Urges Gilead To 'Make History' With Game-changing HIV Drug

Gilead could bring the AIDS pandemic towards an end if the US pharmaceutical giant opens up access to its game-changing new HIV drug, the head of UNAIDS told AFP. Winnie Byanyima urged Gilead to "make history" by allowing generic manufacturing of Lenacapavir, a twice-yearly injectable antiretroviral medication used to treat…

Barchart

Gilead Sciences' Q2 2024 Earnings: What to Expect

Gilead Sciences is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit increase.

Investors Business Daily

Why A Broken Wing Butterfly Might Make Money In Gilead Sciences Stock

Support for Gilead shares sits near 57.

Investors Business Daily

Gilead Flashes A Bullish Sign After HIV Drug Proves 100% Effective

Gilead stock surged Thursday after its twice-annual shot proved 100% effective in preventing HIV infections in cisgender women.

Barchart

Is Gilead Sciences Stock Underperforming the Nasdaq?

Gilead Sciences has recently underperformed the broader Nasdaq Composite, but analysts are reasonably bullish about the stock’s outlook.

Investors Business Daily

Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender

Gilead stock reversed lower Monday after confirming it's testing a popular weight-loss mechanism as a treatment for a liver disease.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.